DJIA 17,949.59 -85.34 -0.47%
NASDAQ 5,014.10 19.50 0.39%
S&P 500 2,097.29 -3.11 -0.15%
market minute promo


company name or ticker
Company Photos
(Click to zoom)

Israel ETFs in Focus on Surprise Rate Cut - ETF News And Commentary

5 Things Biogen Idec Inc's Management Wants You to Know

Pipeline data, new drug launches, and sales of established drugs top the list.

10 cheapest stocks in the Nasdaq’s hottest sector

Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary an

Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints

$20 Billion Market: What’s the Best Stock to Buy?

Three drug companies to watch as biologics come off patent and investors anticipate a biosimilar boom -- here's what you need to know.

Why Momenta Pharmaceuticals, Inc. Jumped Higher Today

Momenta shares rose by more than 10% earlier today on optimism it will overcome headwinds.

Actavis Barred from Selling Generic Pulmicort Respules - Analyst Blog

Teva to Commercialize Eagle's Cancer Drug in the U.S. - Analyst Blog

Health Care Sector Update for 02/18/2015: EGRX, CAPN, MDAS, TEVA

Waiting for the Momenta to Regain

Momenta Pharmaceuticals waits on potential partner(s), the FDA, and the court system.